About Colossal
Colossal Biosciences is an American biotechnology and genetic engineering company, founded in 2021, that pioneers de-extinction using CRISPR and advanced genomic technologies to revive extinct species such as the woolly mammoth, Tasmanian tiger, dire wolf, and dodo. The company also develops genomic tools to protect critically endangered species and restore ecosystems. It monetizes its conservation biotechnologies through commercial spinouts and technology licensing.
Company details
Funding
Total raised
$555M
Last stage
Series C
Investors
Founders
Ben Lamm
Serial technology entrepreneur with 5 prior exits (to Accenture, Zynga, LivePerson, and others). Co-founded Colossal Biosciences in 2021 with George Church to pursue de-extinction using CRISPR and genetic engineering.
LinkedIn
George Church
Harvard geneticist, Professor of Genetics at Harvard Medical School, and Professor of Health Sciences and Technology at Harvard and MIT. Pioneer in CRISPR gene editing and synthetic biology.
LinkedIn
Brian Beard
Corporate attorney with extensive experience in M&A, IPOs, and venture capital financings; advises management teams and boards on corporate strategy and governance.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.